AbbVie, Others Move To End Generic Bystolic Antitrust Claims

Law360 (February 9, 2021, 10:42 PM EST) -- AbbVie Inc. and subsidiaries have fired back against a consolidated class action accusing the drug giant of reaping millions of dollars in profit by paying competitors to delay generic forms of the blood pressure drug Bystolic, arguing in a dismissal motion that some buyers lack standing to assert various state antitrust and consumer-protection claims.

The city of Baltimore and several union benefits and welfare funds, also referred to as indirect or end-payor buyers, alleged in New York federal court on Monday that AbbVie and seven subsidiaries under the Allergan and Forest Laboratories names used reverse payments — an antitrust scheme known...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!